A carregar...
Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
BACKGROUND: Surgical resection has remained the mainstay of treatment of GIST with a 5-year-survival of 28–35%. Tyrosine kinase inhibitor (Imatinib) has revolutionised the treatment of these tumours. The current research is directed towards expanding the role of this drug in the treatment of GIST. W...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2491627/ https://ncbi.nlm.nih.gov/pubmed/18644105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-7819-6-77 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|